Kymera Investor Day Presentation Deck
Key Eligibility Criteria:
R/R B-cell lymphoma
Ⓡ
●
KT-413: Clinical Study Design and Objectives
Primary Objective:
• To evaluate safety, PK/PD in
Ⓡ
> 2 prior systemic regimens
Ineligible or refused CAR-T or
ASCT
●
Study Endpoints:
Primary: Safety, tolerability,
MTD/RP2D
Secondary: PK, preliminary
efficacy
Exploratory: Target
MYD88 mutant and MYD88
wild-type R/R DLBCL
(IRAK4/Ikaros/Aiolos)
knockdown and downstream
effects in PBMC, and tumor
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
DL1
Phase 1a
Dose Escalation & MTD/RP2D
Expansion
DL2
DLX
Protocol
Amendment
KT-413 +
SOC
Combo
MTD/RP2D
Expansion
Protocol
Amendment
DL1-DLX
DL1 DLx→
KYMERA R&D DAY - December 16th, 2021
MTD/RP2D
Expansion
MTD/RP2D
Expansion
Phase 1b
Dose Expansion
MyD88MT DLBCL
≥2 prior regimens
MyD88WT DLBCL
≥2 prior regimens
Waldenström's
Macroglobulinemia
Primary CNS Lymphoma
Combination Expansion
Combination Expansion
PAGE 55View entire presentation